Industry Leaders from CAS, West China Hospital and Top Executives Unveil Challenges and Opportunities in Precision Medicine at VBEF 2025
With breakthroughs in gene sequencing technology and the maturation of molecular biology, precision medicine has gradually become a key direction in modern medicine. At its core, precision medicine leverages molecular diagnostic techniques to enable early disease warning, precise diagnosis, and personalized treatment, thereby improving therapeutic outcomes and patient survival rates.
Molecular diagnostics, as a crucial component of precision medicine, has witnessed rapid global development in recent years. Despite this positive trajectory, the field faces several challenges, including high costs, insufficient standardization, excessive technical specialization, low rates of clinical translation, and issues related to data interpretation and privacy protection.
To facilitate high-quality exchanges and explore potential solutions within the precision medicine industry,VCBeat will be on May 10thAt the 2025 VBEF Top 100 Future Healthcare and Pharma Exhibition (VBEF) held at the Suzhou International Expo Center,“Forum on the Development of Precision Medicine and Molecular Diagnostics Industry” Held Concurrently, inviting scientific and clinical experts, molecular diagnostics and gene sequencing companies, and professional investors to attend the conference, jointly promoting the development of the precision medicine industry.
(Information statistics as of April 11; agenda will be updated gradually)
Connect with tech luminaries, leading enterprises, and top-tier investors at VCBeat VBEF
Three Major Modules: Finding the Optimal Solution for Precision Medicine and Molecular Diagnostics
In the Technology Foresight section,Huang Yihua, Tenured Researcher at the Institute of Biophysics, Chinese Academy of Sciences; Geng Jia, Deputy Director of the Clinical Laboratory Medicine Research Center, West China Hospital, Sichuan University; and Guo Xin, Principal Investigator at the Shanghai Institute for Science and IntelligenceWe will separately analyze the progress and insights into gene sequencing, single-molecule biosensing technology, and large life science models.
Innovation Practice Section,Liang Zhikun, Deputy Director of Daan Gene Research Institute; Yang Min, Senior Program Officer at the Bill & Melinda Gates Foundation; Chen Hao, Partner at Guoqian Venture Capital; and Jin Ge, CEO of Rendong MedicineSharing Corporate Innovation Practices: Exploring the Integration of Molecular Diagnostics and Personalized Therapy, Global Expansion Strategies, and the Value Investment Logic of Genetic Testing.
From an ecological perspective,Chang Tingting, Partner at Qiushi Capital and CEO of Fenghuanggu Medical; Jiang Changlong, Sales Director at Anxuyuan Biotechnology; Zhao Weifang, Director of Capital Ecosystem at Fitgene Biology; Liu Xiaowei, General Manager of Deneng Medicine, 3D Medicines DiagnosticsA roundtable discussion on the “Opportunities and Challenges in Precision Diagnosis and Treatment” will be held.
Aggregating Resources Across the Precision Diagnosis and Treatment Industry to Drive Efficient Industrial Collaboration
To foster in-depth exchange and collaboration among stakeholders in the precision diagnosis and treatment industry, VCBeat is concurrently hosting a series of N+ activities during VBEF, including government-enterprise closed-door meetings, premium asset promotion sessions, and innovative product launch events.By adopting the “exhibition + forum + transaction” trinity model, it forges deep connections between high-quality assets and global capital, local industrial chains, and end-user medical institutions, facilitating the leap of China’s innovative healthcare and pharmaceutical assets from “innovation capability” to “productivity.”
The Exhibition Achieves Diversified Matchmaking:2025 VBEF Specially Designed Exhibition AreaCenter Stage (Thematic Roadshows, Product Launches), Innovative Product Showcase (Product Demonstrations, Case Studies)、Innovative Assets Poster Exhibition (Top 100 Investment Landscape, Resource Matchmaking)Three Major Value Domains: Accelerating the Value Fission of High-Quality Assets in China’s Medical and Pharmaceutical Innovation Through Innovative Models and Efficient Mechanisms.
Forum Decoding Trends:2 Main Forums, 4 Featured Forums, and 20+ Thematic Forums comprehensively cover the hot sectors of high-quality innovative assets in China’s healthcare and pharmaceutical industries. Over 300 industry leaders, academicians, experts, and corporate executives discuss growth poles in China’s healthcare industry, precisely identifying growth drivers for high-quality assets.
High-Efficiency Trading Scenarios:Exhibiting companies can engage directly with international buyers, overseas distributors, and supply chain partners. Through on-site negotiations and demand-matching sessions, they can swiftly secure business opportunities in cross-border cooperation, technology introduction, and product distribution, thereby facilitating the integration of China’s high-quality innovative medical and pharmaceutical assets into the global industrial chain.
Registration Open to Industry Partners, engage in direct communication and negotiate collaborations with innovative enterprises.
Free tickets available—limited quantity, first come, first served!
Share this article/poster to your WeChat Moments and collect 18 likes,
Add the Organizing Committee (Note: Ticket Benefits),
Get a ticket worth 399 yuan (excluding meals)!
Ms. Jing, Organizing Committee
Exhibition Name:2025 VBEF Future Healthcare & Pharma Top 100 Expo
Exhibition Dates:May 9–10, 2025
Exhibition Venue:China · Suzhou · International Expo Center
Exhibition Scale:16,000+ visits
(More partners to be confirmed. Stay tuned to VBEF for the latest updates.)
Organizer:VCBeat
Co-organized by:VCBeat New Medicine, ATLATL Innovation Center, Enshe Family Office, Dr. Fang, Guoke Hengtai, He Eye Hospital, JD Health, Health Growth Society, Niukou Capital, Probe Capital, China Optics Valley, Optics Valley Select
Forum Support Units:MathWorks, Pivotal bioVenture, Alibaba DAMO Academy, Anjieming, Aoruiji, Bose Quantum, Bohe Innovation Center, Deneng Medicine, Dongmai Medical, Enshe Family Office, Fanzhuo Group, Fuxin Sci-Tech Innovation, Gerui, Guotai Junan, He Eye Specialist Hospital, Hengxu Capital, Hunan Provincial Medical Device Industrial Park, Huamei Haolian, Huimei Digital Technology, Health Road, Jieshi Medical, JD Health, Jinghan New Materials, Legend Star, Linsheng Polymer, Lulutong Health, Lide Health, Mi Jian, Naiterui, Ping An Good Doctor, Puchuang Medical, Ruisen Medical, Shangyong Technology, Taozi Health, Tonghe Litai, Tupai Medical, Weimei Health, Xiyi Medicine, Xikang Cloud Hospital, Xinhong Electronics, Yanyin Technology, Yishu Health, Yijiada Medical, Zhejiang Ka Yi, Knowledge Matrix, Jones Lang LaSalle, China Pharmaceutical University Suzhou Alumni Association, Zhongrui Pharmaceutical Business School
Supporting Organizations for the Ranking:Proxima Ventures, Boyuan Capital, Bencao Capital, Changfa Group, Chende Capital, Changling Capital, Daotong Investment, Panlin Capital, Danlu Capital, GTJA Investment, Sequoia China, Honghui Fund, Huagai Capital, Legend Capital, Matrix Partners China, Legend Star, Qingsong Capital, Qiming Venture Partners, Shenzhen Capital Group, Shanghai Industrial Capital, Xianfeng Qiyun, Sunshine Ronghui Capital, Yuanhe Origin, Yuansheng Venture Capital, Yuanyi Capital
Supported Industrial Parks:Changping Life Valley Industrial Base, Optics Valley Bio-City/Wuhan Gaoke Medical Device Park, Haicheng Digital Medical Industry Park, Jiangsu Medical Device Technology Industrial Park, Shanghai Free Trade Zone No. 1 Life Science and Technology Industrial Park, Guangdong-Hong Kong-Macao Greater Bay Area Biosafety Innovation Port, Zhongguancun (Tongzhou) Innovative Medical Translation Industrial Park (Yifang Health Valley)
Exhibition Support Media:21st Century Business Herald, E-Pharma Academy, MedWorld Device World, Bioon Valley, TouchBio, Cyzone, Big Health Pie, Haodeya, Huihui Yaoka, Jixiao 361, Jiankangjie, Kuaizi Wenyisheng, Bioon, Shouxiezhe, Taidu TIMEDOO, Tansibio, VCBeat, Sina Medicine, Xiaofanzhuo, Xinxi Xia, Yao Fangzhou, Yaokahui, YAOZH, Yaopeng Xieyou, Yi Gong Xueren, Yi Qianyan, Yixuejie, Pharmaceutical Manager, PharmaCube, Zhiyi Xun